Menarini Silicon Biosystems Announces study results to be presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating Multiple Myeloma Cells
Topics: CELLSEARCH, Liquid biopsy, Multiple myeloma, Dana-Farber Cancer Institute, Multiple Myeloma Research Foundation
As the market leader in cell-based liquid biopsies, Menarini Silicon Biosystems is offering community hematology-oncologists an opportunity to have patient blood samples sent to a US centralized laboratory where its CELLSEARCH® technology can enumerate Circulating Multiple Myeloma Cells (CMMCs) for non-invasive monitoring of disease
Topics: CELLSEARCH, Liquid biopsy, Multiple myeloma, CLIA Lab, LDT
This non-invasive test leverages the Gold Standard CELLSEARCH platform to enumerate Circulating Endothelial Cells from blood and may provide novel and valuable information on systemic sclerosis disease. The test is available to all professionals as a lab service in Europe and the US.
Topics: CELLSEARCH, CECs, Circulating Endothelial Cells, Lab Services, Systemic Sclerosis
The new test, available as a Lab Service throughout Europe and US, leverages the Gold Standard CELLSEARCH platform to enumerate Circulating Multiple Myeloma Cells from blood and offers real-time standardized monitoring of multiple myeloma in clinical research studies.
Topics: CELLSEARCH, Multiple myeloma, CMMCs, Lab Services
CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood
Topics: CTCs, CELLSEARCH, Liquid biopsy, Blood Enrichment, CellMag
Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome
Topics: CELLSEARCH, metastatic breast cancer, HER2, San Antonio Breast Cancer Symposium, CTC phenotyping
Robust pooled analysis demonstrating how CTC count may help to optimize treatment choices
Topics: CELLSEARCH, metastatic breast cancer, global pooled analysis, San Antonio Breast Cancer Symposium
First randomized clinical trial demonstrating that CTC count may help personalize treatment choices
Topics: CELLSEARCH, metastatic breast cancer, STIC
Researchers Use Menarini’s Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment
Topics: CELLSEARCH, metastatic breast cancer, Multiple myeloma, HER2, AACR
Strategic partnership will focus on commercializing CELLSEARCH platform for
COVID-19 related use cases, along with other COVID-19 related products
Topics: CELLSEARCH, COVID-19, OpGEN
©2020 Menarini Silicon Biosystems. All rights reserved. This site is published by Menarini Silicon Biosystems which is solely responsible for its contents.
The products/services discussed are for research use only and not for use in diagnostic procedures (except as specifically noted).
